Patents Assigned to Incyte Corporation
  • Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders
    Patent number: 9932341
    Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 3, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Song Mei, Brent Douty
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 9926301
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 27, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Song Mei
  • Heterocyclic compounds useful as pim kinase inhibitors
    Patent number: 9920032
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: March 20, 2018
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
    Patent number: 9918990
    Abstract: The present invention relates to compounds represented by the general Formula I which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 20, 2018
    Assignee: Incyte Corporation
    Inventors: Eddy W. Yue, Andrew P. Combs, Brent Douty
  • Secreted proteins
    Patent number: 9914921
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: March 13, 2018
    Assignee: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
  • Processes for preparing pyrazolyl-substituted pyrrolo[2,3-d]pyrimidines
    Patent number: 9908888
    Abstract: The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: March 6, 2018
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Jiacheng Zhou, Pingli Liu, Qiyan Lin, Brian W. Metcalf, David Meloni, Yongchun Pan, Michael Xia, Mei Li, Tai-Yuen Yue, James D. Rodgers, Haisheng Wang
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 9908895
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: March 6, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
    Patent number: 9890162
    Abstract: The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 13, 2018
    Assignee: Incyte Corporation
    Inventors: Yaping Sun, Hao Feng, Yun-Long Li, Song Mei, Jun Pan, Anlai Wang, Hai-Fen Ye, Ke Zhang
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 9890156
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 13, 2018
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Methods for detecting expression levels of human signal peptide-containing proteins (HSPP)
    Patent number: 9885717
    Abstract: The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: February 6, 2018
    Assignee: INCYTE CORPORATION
    Inventors: Preeti G. Lal, Y. Tom Tang, Gina A. Gorgone Simone, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Ingrid E. Akerblom, Janice K. Au-Young, Henry Yue, Chandra S. Arvizu, Roopa M. Reddy, Jennifer L. Jackson, Olga Bandman
  • Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
    Patent number: 9879010
    Abstract: The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: January 30, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Haisheng Wang, Andrew P. Combs, Richard B. Sparks
  • Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
    Patent number: 9873688
    Abstract: The present application is directed to processes and intermediates for making 4-({2-[(aminosulfonyl)amino]ethyl}amino)-N-(3-bromo-4-fluorophenyl)-N?-hydroxy-1,2,5-oxadiazole-3-carboximidamide, which is an inhibitor of indoleamine 2,3-dioxygenase, useful in the treatment of cancer and other disorders.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Ming Tao, William Frietze, David J. Meloni, Lingkai Weng, Jiacheng Zhou, Yongchun Pan
  • Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
    Patent number: 9873698
    Abstract: The present invention relates to certain spirocyclic compounds that are inhibitors of 11-? hydroxyl steroid dehydrogenase type 1 (11?HSD1), compositions containing the same, and methods of using the same for the treatment of diabetes, obesity and other diseases.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 23, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Colin Zhang
  • Salts of a pim kinase inhibitor
    Patent number: 9862705
    Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: January 9, 2018
    Assignee: Incyte Corporation
    Inventors: Zhongjiang Jia, Ganfeng Cao, Yongchun Pan, Vaqar Sharief, Jiacheng Zhou
  • Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors
    Patent number: 9849120
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 26, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
  • Tricyclic heterocycles as BET protein inhibitors
    Patent number: 9850257
    Abstract: The present invention relates to tricyclic heterocycles of Formula (I), which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 26, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie
  • Heterocyclic compounds and uses thereof
    Patent number: 9840503
    Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of the TAM protein kinases and are useful in the treatment of TAM-associated diseases such as cancer.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: December 12, 2017
    Assignee: Incyte Corporation
    Inventors: Yaping Sun, Yun-Long Li, David M. Burns
  • Tricyclic heterocycles as bet protein inhibitors
    Patent number: 9834565
    Abstract: The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: December 5, 2017
    Assignee: Incyte Corporation
    Inventors: Andrew P. Combs, Richard B. Sparks
  • Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
    Patent number: 9822124
    Abstract: The present disclosure describes bicyclic heteroaromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: November 21, 2017
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li
  • N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
    Patent number: 9815839
    Abstract: The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 14, 2017
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Andrew P. Combs, Eddy W. Yue, Thomas P. Maduskuie, Jr., Richard B. Sparks